METIS TECHBIO-P's stock plummeted 12.26% during intraday trading, continuing a downward trend that began after its highly anticipated initial public offering.

The AI drug delivery company, which saw its shares surge 173% on its debut, is facing sustained selling pressure as early-stage commercialization challenges become apparent. The company has accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue streams.

Adding to the downward pressure, certain internationally placed shares carry no lock-up restrictions, allowing early investors to exit positions and take profits. The fading enthusiasm that typically follows new listings has accelerated this correction phase as the market reassesses the company's fundamentals.